However, it has been clearly shown in adoptive T cell transfer studies in preclinical melanoma models that more differentiated CD8+ effector T cells are less effective for in vivo tumor treatment and that the renewal capacity of CD8+ T cells as determined by their telomer length plays an important role in that respect (25). The gene discussed is CD8A; the disease is neoplasm.